RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Other EventsItem 9.01Other Events.
On December 15, 2017, Radius Health, Inc. (the “Company”) issued a press release announcing that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), will issue a third Day-180 List of Outstanding Issues in the process of their ongoing regulatory review of the Company’s marketing authorization application for abaloparatide for subcutaneous injection.A copy of the press release is filed as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated December 15, 2017. |
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated December 15, 2017. |
Radius Health, Inc. ExhibitEX-99.1 2 rdus-ex991_50.htm EX-99.1 rdus-ex991_50.htm Exhibit 99.1 Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC,…To view the full exhibit click here
About RADIUS HEALTH, INC. (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.